vs
Side-by-side financial comparison of Scilex Holding Co (SCLX) and Taysha Gene Therapies, Inc. (TSHA). Click either name above to swap in a different company.
Taysha Gene Therapies, Inc. is the larger business by last-quarter revenue ($5.5M vs $4.8M, roughly 1.1× Scilex Holding Co). Taysha Gene Therapies, Inc. runs the higher net margin — -507.8% vs -961.9%, a 454.2% gap on every dollar of revenue. On growth, Taysha Gene Therapies, Inc. posted the faster year-over-year revenue change (171.3% vs -67.8%). Over the past eight quarters, Taysha Gene Therapies, Inc.'s revenue compounded faster (26.8% CAGR vs -33.6%).
Scilex Holding Co is a commercial-stage biopharmaceutical firm focused on developing and commercializing innovative non-opioid pain management therapies for acute and chronic pain segments. It primarily serves the US market, offering prescription and over-the-counter pain relief solutions for patients and healthcare providers.
Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company specializing in developing adeno-associated virus (AAV)-based gene therapies for rare monogenic central nervous system disorders with high unmet medical needs. Its core pipeline targets serious life-threatening neurological conditions, with primary operations and market focus across North America and European regions.
SCLX vs TSHA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $4.8M | $5.5M |
| Net Profit | $-46.1M | $-27.9M |
| Gross Margin | 45.5% | — |
| Operating Margin | -2317.8% | -516.0% |
| Net Margin | -961.9% | -507.8% |
| Revenue YoY | -67.8% | 171.3% |
| Net Profit YoY | -613.7% | -48.3% |
| EPS (diluted) | $-4.63 | $-0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $4.8M | $5.5M | ||
| Q3 25 | $10.6M | $0 | ||
| Q2 25 | $9.9M | $2.0M | ||
| Q1 25 | $5.0M | $2.3M | ||
| Q4 24 | $14.9M | $2.0M | ||
| Q3 24 | $14.4M | $1.8M | ||
| Q2 24 | $16.4M | $1.1M | ||
| Q1 24 | $10.9M | $3.4M |
| Q4 25 | $-46.1M | $-27.9M | ||
| Q3 25 | $-257.8M | $-32.7M | ||
| Q2 25 | $-44.0M | $-26.9M | ||
| Q1 25 | $-26.1M | $-21.5M | ||
| Q4 24 | $-6.5M | $-18.8M | ||
| Q3 24 | $-4.4M | $-25.5M | ||
| Q2 24 | $-37.6M | $-20.9M | ||
| Q1 24 | $-24.4M | $-24.1M |
| Q4 25 | 45.5% | — | ||
| Q3 25 | 68.5% | — | ||
| Q2 25 | 66.9% | — | ||
| Q1 25 | 72.3% | — | ||
| Q4 24 | 68.5% | — | ||
| Q3 24 | 73.9% | — | ||
| Q2 24 | 73.2% | — | ||
| Q1 24 | 64.7% | — |
| Q4 25 | -2317.8% | -516.0% | ||
| Q3 25 | -1766.2% | — | ||
| Q2 25 | -207.2% | -1347.1% | ||
| Q1 25 | -557.5% | -930.5% | ||
| Q4 24 | -190.5% | -985.8% | ||
| Q3 24 | -138.0% | -1448.4% | ||
| Q2 24 | -95.4% | -1915.4% | ||
| Q1 24 | -179.0% | -713.3% |
| Q4 25 | -961.9% | -507.8% | ||
| Q3 25 | -2441.5% | — | ||
| Q2 25 | -445.1% | -1353.6% | ||
| Q1 25 | -521.2% | -935.2% | ||
| Q4 24 | -43.4% | -929.0% | ||
| Q3 24 | -30.4% | -1427.5% | ||
| Q2 24 | -229.6% | -1882.0% | ||
| Q1 24 | -224.0% | -705.4% |
| Q4 25 | $-4.63 | $-0.08 | ||
| Q3 25 | $-22.17 | $-0.09 | ||
| Q2 25 | $-7.42 | $-0.09 | ||
| Q1 25 | $-2.26 | $-0.08 | ||
| Q4 24 | $8.53 | $-0.07 | ||
| Q3 24 | $-0.58 | $-0.10 | ||
| Q2 24 | $-7.67 | $-0.09 | ||
| Q1 24 | $-8.33 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $319.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-207.8M | $246.9M |
| Total Assets | $365.0M | $343.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.0M | $319.8M | ||
| Q3 25 | $878.0K | $297.3M | ||
| Q2 25 | $4.1M | $312.8M | ||
| Q1 25 | $5.8M | $116.6M | ||
| Q4 24 | $3.3M | $139.0M | ||
| Q3 24 | $77.0K | $157.7M | ||
| Q2 24 | $6.9M | $172.7M | ||
| Q1 24 | $1.8M | $124.0M |
| Q4 25 | $-207.8M | $246.9M | ||
| Q3 25 | $-176.9M | $219.0M | ||
| Q2 25 | $-249.0M | $248.7M | ||
| Q1 25 | $-211.5M | $55.1M | ||
| Q4 24 | $-192.6M | $71.5M | ||
| Q3 24 | $-211.3M | $88.8M | ||
| Q2 24 | $-214.7M | $108.9M | ||
| Q1 24 | $-189.8M | $53.8M |
| Q4 25 | $365.0M | $343.3M | ||
| Q3 25 | $275.9M | $316.6M | ||
| Q2 25 | $83.8M | $333.3M | ||
| Q1 25 | $79.0M | $138.4M | ||
| Q4 24 | $93.0M | $160.4M | ||
| Q3 24 | $100.4M | $180.2M | ||
| Q2 24 | $104.5M | $200.4M | ||
| Q1 24 | $91.2M | $153.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-17.5M | $-26.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-17.5M | $-26.7M | ||
| Q3 25 | $8.2M | $-24.2M | ||
| Q2 25 | $7.0M | $-20.2M | ||
| Q1 25 | $6.0M | $-22.0M | ||
| Q4 24 | $2.5M | $-18.3M | ||
| Q3 24 | $5.1M | $-21.6M | ||
| Q2 24 | $2.3M | $-21.5M | ||
| Q1 24 | $9.4M | $-19.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | $-24.3M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-18.3M | ||
| Q3 24 | — | $-21.6M | ||
| Q2 24 | — | $-21.7M | ||
| Q1 24 | — | $-19.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -905.5% | ||
| Q3 24 | — | -1210.9% | ||
| Q2 24 | — | -1951.9% | ||
| Q1 24 | — | -584.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | 0.0% | 2.0% | ||
| Q2 24 | — | 18.1% | ||
| Q1 24 | — | 4.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
